Ten Preclinical Studies and the Potential to Improve the Aging Process

Well-known characteristics of aging are the loss of skeletal muscle mass and a general decline in all of the organs in the body. The speed of decline coincides with the coenzyme NAD (nicotinamide adenine dinucleotide) levels.

According to an article in Biospace, ChromaDex Corp. recently announced positive results stemming from ten published preclinical trials investigating Niagen® (nicotinamide riboside or NR).

About Niagen®

The preclinical studies illustrate Niagen’s potential to boost cellular health sufficiently to reduce or control the progression of various degenerative conditions.

Researchers pointed to Niagen’s success in raising NAD levels in preclinical studies of circadian rhythms, fertility, and aging, as well as one clinical study of liver function.

The NAD levels in younger tissues and cells are higher. Younger people usually have a more robust schedule of activities, mental stimulation, and a greater potential for cell repair.

ChromaDex has facilitated several studies through CERP, its research program, that makes its patented Niagen ingredient available without cost to universities and research institutions.

About NR Preclinical Studies

  • To further support NR research in cardiovascular health, a recent report in Biochemical Pharmacology stated that in the lab, nicotinamide riboside reduced inflammation in endothelial cells in mice. The endothelial cells are the primary type of cells found in the heart and in lymph and blood vessels.
  • CERP sponsored a small pilot study involving NR in healthy individuals. Researchers in this study found that NR, combined with certain nutrients, showed an improvement in liver function biomarkers. These findings bode well for markers in non-alcoholic fatty liver disorder.
  • A third study found that NR generated a more youthful circadian rhythm (our internal clock) in older mice. After supplementation with NR, it was observed that the older mice regained cellular function similar to that of younger mice. The older mice also became more physically active. Boosting NAD levels with NR showed the potential to possibly maintaining fertility.
  • Gulf War Illness, a mitochondrial disease, refers to medical issues that have plagued veterans for decades. Mitochondria produce ninety percent of all the energy our body requires in order to function. The symptoms include muscle and joint pain, fatigue, and gastrointestinal disorders. A study using mouse models of this rare disease found NR lessened fatigue and showed anti-inflammatory effects in the mice. NR also improved mitochondrial function.

The Next Level

The encouraging results of the preclinical studies have prompted more research to ascertain Niagen’s full potential.

To date, CromaDex invested over thirty-five million dollars in commercializing and developing NR.

ChromaDex Corp.

ChromaDex Corp. is focused on improving the aging process. The company partners with research institutions and universities worldwide in the development, discovery, and creation of solutions to meet NAD’s full potential.

Niagen® is supported by scientific and clinical research. It is sold to consumers under the registered name of Tru Niagen®.

What are your thoughts about a product that is being developed as a way to slow the aging process? Do you think it has any actual benefits? Share your stories, thoughts, and hopes with the Patient Worthy community!

Rose Duesterwald

Rose Duesterwald

Rose became acquainted with Patient Worthy after her husband was diagnosed with Acute Myeloid Leukemia four years ago. He was treated with a methylating agent While he was being treated with a hypomethylating agent, Rose researched investigational drugs being developed to treat relapsed/refractory AML.

Share this post

Share on facebook
Share on google
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email